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Abstract
Background: Hyperglycemia is among the major side effects of dexamethasone (DEX). Glucose or glucocorticoid
(GC) regulates the expression of thioredoxin-interacting protein (TXNIP) that controls the production of reactive
oxygen species (ROS) through the modulation of thioredoxin (TRX) activity.
Methods: Multiple myeloma (MM) cells were grown in 5 or 20 mM/L glucose with or without 25 μM DEX.
Semiquantitative reverse transcription-PCR (RT-PCR) was used to assess TXNIP RNA expression in response to
glucose and DEX. ROS were detected by 5-6-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate (CM-H2DCFDA).
TRX activity was assayed by the insulin disulfide-reducing assay. Proliferation was evaluated using CellTiter96
reagent with 490-nm absorbtion and used to calculate the DEX IC50 in 20 mM/L glucose using the Chou’s dose
effect equation.
Results: TXNIP RNA level responded to glucose or DEX with the same order of magnitude ARH77 > NCIH929 >
U266B1 in these cells. MC/CAR cells were resistant to the regulation. ROS level increased concurrently with reduced
TRX activity. Surprisingly glucose increased TRX activity in MC/CAR cells keeping ROS level low. DEX and glucose
were lacking the expected additive effect on TXNIP RNA regulation when used concurrently in sensitive cells. ROS
level was significantly lower when DEX was used in conditions of hyperglycemia in ARH77/NCIH9292 cells but not
in U266B1 cells. Dex-IC50 increased 10-fold when the dose response effect of DEX was evaluated with glucose in
ARH && and MC/Car cells
Conclusions: Our study shows for the first time that glucose or DEX regulates important components of ROS
production through TXNIP modulation or direct interference with TRX activity in MM cells. We show that glucose
modulates the activity of DEX through ROS regualtion in MM cells. A better understanding of these pathways may
help in improving the efficacy and reducing the toxicity of DEX, a drug still highly used in the treatment of MM.
Our study also set the ground to study the relevance of the metabolic milieu in affecting drug response and
toxicity in diabetic versus non-diabetic patients with MM.
Background
Despite the booming of novel agents for the treatment
of multiple myeloma (MM) such as proteasome inhibi-
tor bortezomib, and immuno-modulator agents thalido-
mide or lenalidomide, dexamethsone (DEX) remains
one of the most active agents in the treatment of this
disease [1]. In fact, most of the combinations with the
n o v e la g e n t ss t i l li n c l u d eD E Xa sab a c k b o n e[ 1 ] .
Furthermore, single agent DEX has represented the con-
trol arm in the studies that have assessed efficacy and
safety of the novel agent combinations [2,3]. Although
the efficacy of DEX-based combinations has been widely
proven, DEX is associated with notable toxicity either as
single agent or in combination with novel agents. A
recent study has shown similar efficacy but with less
toxicity by reducing the dose of DEX in combination
with the novel agent lenalidomide [4]. Hyperglycemia is
among the major side effects of DEX and none of the
studies has addressed the question whether the action of
DEX is different in condition of hyperglycemia versus
normoglycemia in treated MM patients. We have pre-
viously shown that hyperglycemia regulates thioredoxin
(TRX) activity-reactive oxygen species (ROS) through
induction of thioredoxin-interacting protein (TXNIP) in
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We also showed that hyperglycemia-regulated TXNIP-
ROS-TRX axis was relevant for the response of MDA-
MB-231 cells to paclitaxel cytotoxicity [6]. Based on
both observations that DEX induces hyperglycemia and
that hyperglycemia may interfere with the cell response
to drugs, we investigated the axis TXNIP-ROS-TRX in
conditions of increased level of glucose (e.g., mimicking
in vivo conditions of hyperglycemia) and in response to
DEX in a pool of cells derived from multiple myeloma.
Our results set the track for further investigating the
relevance of metabolic conditions of the patients with
multiple myeloma and response to therapy.
Materials and methods
Cell lines and tissue culture
Multiple myeloma-derived cell lines NCIH929, ARH77,
U266B1 and MC/CAR were purchased from American
Type Culture Collection (Manassas, VA). Dexametha-
sone and phloretin were purchased from Sigma-Aldrich
(St. Louis, MO) Cells were routinely cultured in
RPMI1640/10%FBS/5 mM glucose. For chronic hyper-
glycemia conditions, cells were chronically grown in
RPMI 1640/10% FBS containing 20 mM glucose. For
dexamethasone response cells were cultured in either 5
or 20 m chronically and dexamethasone (25 uM) added
to media for 24 hours prior to harvest. Glucose uptake
inhibition studies were accomplished by adding phlore-
tin (200 uM) to media and cells harvested after 24
hours.
TXNIP RT-PCR, ROS assay and TRX activity
All experiments were run in triplicate for analysis. Cells
were harvested and each sample split into three aliquots
for RNA isolation, ROS and TRX activity analysis. Total
RNA was isolated using Aquapure RNA isolation kit
(Bio-Rad, Hercules, CA) and first strand c-DNA synth-
esis by iScript c-DNA amplification kit (Bio-Rad)
according to manufacture’s protocol. Primers and PCR
conditions were as previously described [5]. We have
previously shown that increased RNA correlates with
level of TXNIP protein [5]. ROS were detected by 5-6-
chloromethyl-2’,7 ’-dichlorodihydrofluorescein diacetate
(CM-H2DCFDA) and measured for mean fluorescence
intensity by flow cytometry as previously described [5].
TRX-activity was assessed by the insulin disulfide assay
as previously described [5]. Fold-change (> 1 versus < 1
fold increase/decrease, 1 = no change) was obtained for
each cell line. Cell lines which showed response
(NCIH929, ARH77, U266B1) were further grouped and
compared to non-responsive MC/CAR cell line.
Dexamethasone IC50 calculation
IC 50 were calculated by the method of Chou and Tala-
lay using Calcusyn software (Biosoft, Cambrigdge UK)
Statistical analysis
Differences between treatments were evaluated by
ANOVA or student’s t-test and accepting as significant
differences if p < 0.05.
Results
Differences in TXNIP-ROS-TRX axis-response to
hyperglycemia in MM cells
We assessed the TXNIP RNA level, ROS production
and TRX activity in response to isolated hyperglycemia.
The function of TXNIP as a modulator of the redox sys-
tem through the binding of the TRX active cysteine resi-
dues has been elucidated [7,8]. Furthermore, the
promoter region of the TXNIP gene contains carbohy-
drate responsive elements (ChoRE) conferring the
responsiveness of the gene directly to glucose [9,10]. We
have also recently shown that there is strong correlation
between TXNIP RNA and TXNIP protein level to justify
our decision to assess only RNA levels in the cells [5].
Hyperglycemia [20 mM versus 5 mM glucose] signifi-
cantly affected the fold-change of increased levels of
TXNIP RNA level (mean 1.37 ± 0.17) and ROS level
(mean 1.70 ± 0.25) in NCIH9292, ARH77 and U266B1
cells (Figure 1A). As expected TRX activity concurrently
declined an average of 0.77 ± 0.12 in the same cell lines
(Figure 1C). Unexpectedly, glucose induced an increase
in TRX activity (1.6 ± 0.13 fold) associated with
decreased ROS activity (0.38 ± 0.06 fold), and
unchanged TXNIP RNA level in MC/CAR cells (Figure
1A-C). These results clearly show that TXNIP RNA reg-
ulation by hyperglycemia varies among multiple mye-
loma cell lines with a grading in response ARH77 >
NCIH929 > U266B1 as compared to non-responder
MC/CAR cells (Figure 1A-C). This effect translates in a
consequent grading of reduced TRX activity and
increased ROS level by the same order in these cell
lines. On the other hand, hyperglycemia seems to have a
protective effect by increasing TRX activity and reducing
ROS level in MC/CAR cells, the ones not responding to
glucose-TXNIP regulation. This effect hampers ROS
production in the same cell line.
Response of the TXNIP-ROS-TRX axis to DEX in conditions
of hyperglycemia
DEX induces hyperglycemia by itself as adverse event in
some patients. Furthermore, recent studies have demon-
strated that TXNIP gene contains glucocorticoid-
responsive elements (GC-RE) and it has been described
as prednisolone-resp o n s i v eg e n ei na c u t el y m p h o b l a s t i c
leukemia cells [11,12]. We decided to study the response
of TXNIP-ROS-TRX axis in vitro as a mimicker of the
in vivo situation involving a patient who either experi-
ences GC-induced hyperglycemia or uses DEX in a con-
dition of existing frank diabetes. Our expectations were
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amplifying the ROS production and the oxidative stress.
When DEX was added to cells grown in condition of
hyperglycemia, no additive effect was seen in NCIH929,
ARH77 and U266B1 cell lines. The mean TXNIP
response was similar with DEX (mean 1.29 ± 0.17) or
without it (mean 1.37 ± 0.19) in the same three cell
lines (e.g., compare Figure 1A and 2A). ROS levels were
significantly lower as compared to isolated hyperglyce-
mia in NCIH929 and ARH77 cells but unchanged in
Figure 2 Hyperglycemia and dexamethasone (DEX) do not have an additive effect on TXNIP-ROS-TRX.C e l l sw e r eg r o w ni n2 0m M
glucose (GLC) ± dexamethasone (25 μM) (DEX) for 24 h. Data is represented as fold change over 20 mM baseline, with > 1 fold change
indicating an increase over baseline and < 1 a decrease over baseline levels. Multiple myeloma-derived ARH77, NCIH929 and U266B1, which
showed dex response, were grouped and the mean value ± SD for the group presented above. A. Thioredoxin-interacting protein (TXNIP) RNA
levels. B. Reactive oxygen species (ROS)-levels. C.Thioredoxin (TRX) activity. Black star represents p-value compared to 20 mM GLC alone, cross
indicates p- value of MC/CAR compared to grouped value.
Figure 1 Txnip -ROS- TRX axis regulation by hyperglycemia varies among cell lines. Cells were grown chronically in RPMI 5 or 20 mM
glucose (GLC). Data is represented as fold change over 5 mM baseline, with > 1 fold change indicating an increase over baseline and < 1 a
decrease over baseline levels. Multiple myeloma-derived ARH77, NCIH929 and U266B1, which showed glucose response, were grouped and the
mean value ± SD for the group presented above.. A. Thioredoxin-interacting protein (TXNIP) RNA levels. B. Reactive l oxygen species (ROS)-levels.
C.Thioredoxin (TRX) activity. Black star represents p-value compared to 5 mM, cross indicates p- value of MC/CAR compared to grouped value.
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ent compared to isolated hyperglycemia in all three-cell
lines (Figure 1C and 2C). Paradoxically, the data sug-
gested that DEX was hampering the effect of TXNIP on
ROS level in NCIH929 and ARH77 cells, but not in
U266B1 cells that were less sensitive to TXNIP-ROS-
TRX axis regulation in the first place. More interestingly
DEX significantly decreased ROS level (0.38 ± 06 vs
0.21 ± 0.04, p < 0.05) in MC/CAR cells (Figure 1B and
2B). This event was associated with an increase, though
not significantly different, of TRX activity (1.97 ± 0.12
vs 1.60 ± 0.13, p = 0.07) in the DEX-treated MC/CAR
cells (Figure 1C and 2C). These findings suggested that
DEX was also playing a protective effect from ROS pro-
duction in hyperglycemia TXNIP-TRX insensitive MC/
CAR cells implying the involvement of a different bio-
chemical milieu in these cells.
TXNIP is DEX responsive gene in some MM cells but not
in others
Based on the literature saying that TXNIP gene is
responsive to GC we expected an additive effect of DEX
and glucose on its expression [11,12]. Surprisingly, our
data were opposing this expectation making us wonder-
ing whether TXNIP gene would have responded to DEX
in MM cells in the first place. For this purpose, we trea-
ted cells with DEX in conditions of normoglycemia (5
mM). TXNIP RNA significantly increased in NCIH929
and ARH77 cells, less in U266B1 cells and definitively
remained unchanged in MC/CAR (Figure 3). DEX-
mediated TXNIP RNA level overlapped the same pat-
tern seen with glucose response in the same cell lines:
ARH77 > NCIH929 > U266B1. These data suggest that
glucose and DEX-mediated TXNIP regulation may share
the same regulatory mechanism that varies in MM cells
to the point of absolute unresponsiveness as observed in
MC/MCAR cells. Furthermore, DEX directly increased
TRX actitvity and ROS level in MC/CAR cells grown in
5 mM glucose (data not shown).
Cellular level of glucose regulates TXNIP RNA levels and
ROS in ARH77 cells
To assess whether the glucose-induced increase of
TXNIP RNA and ROS level were regulated by the intra-
cellular level of glucose, we inhibited the transport of
the glucose with phloretin which is an effective though
not specific inhibitor of GLUT1 transporter as pre-
viously shown [5]. For this purpose, we investigated
ARH77 cells that had shown the highest TXNIP RNA
level response compared to the unresponsive MC/CAR
cells (Figure 1A). As expected, phloretin blocked the
hyperglycemia effect on TXNIP RNA level (1.5 ± 0.05
vs. 1.03 ± 0.03, p < 0.01) (Figure 4A) and significantly
reduced ROS (2.1 ± 0.08 vs 1.84 ± 0.14, p < 0.05) in
ARH77 cells (Figure 4B). The addition of phloretin had
no effect on either TXNIP or ROS levels in the MC/
CAR cells (Figure 4A, B). This confirmed that glucose
played a major role in the TXNIP RNA regulation in
responsive cells ARH77.
Hyperglycemia increases the DEX-IC50 in MM cells
At this point our data were suggesting that DEX and
glucose together reduced ROS production in ARH77,
NCIH929 and MC/CAR cells independently from the
TXNIP-TRX regulation. Paradoxically, DEX + glucose
further decreased ROS level by increasing TRX activity
in MC/CAR cells. It seemed that DEX was mitigating
the oxidative stress and ROS production induced by
Figure 3 TXNIP is DEX responsive in some MM cell lines but
not others. Cells were grown in 5 mM glucose (GLC) ±
dexamethasone (25 μM) (DEX) for 24 h. Data is represented as fold
change over 5 mM baseline, with > 1 fold change indicating an
increase over baseline and < 1 a decrease over baseline levels.
Multiple myeloma-derived ARH77, NCIH929 and U266B1, which
showed dex response, were grouped and the mean value ± SD for
the group presented above. Black star represents p-value compared
to 5 mM GLC alone, cross indicates p- value of MC/CAR compared
to grouped value.
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expression. We then decided to test the hypothesis of
TXNIP-independent effect by assessing the cytotoxicity
of DEX in TXNIP-glucose/DEX responsive cells ARH77
and TXNIP-glucose/DEX unresponsive cells MC/CAR.
When the dose response effect to DEX was evaluated in
ARH77 and MC/CAR cells in 20 mM glucose, we found
that hyperglycemia increased the IC50 for both cell lines
by a factor of 10 (ARH77: 48 μM to 510 μM; MC/CAR
36 μMt o3 0 3μM )( F i g u r e5 ) .T h e s ed a t as u g g e s tt h a t
MM cells were more resistant to DEX in conditions of
hyperglycemia, probably because of the hampering effect
of DEX on ROS production as shown in Figure 2.
Discussion
Our study addresses the response of cancerous cells in
conditions of hyperglycemia either related to drug
induction or underlining diabetes. More specifically, the
study addresses the question on how cancerous cells
handle the excess of glucose that a drug as part of the
treatment or the deranged metabolism of the host may
cause. We used a cell model derived from MM because
this disease affects middle aged or older patients who
present a higher incidence of diabetes and are treated
with combinations of drugs that include a GC [1]. DEX
as an example of GC induces hyperglycemia either in
situations of normal glycemia or even in case of diabetes
under insulin therapy or oral antidiabetic drugs. There-
fore, the use of the drug may pose cancerous cells in
metabolic situations the consequences of which onto the
response to the treatment with it are unknown. We have
recently shown that glucose regulates ROS production
through TXNIP regulation and TRX activity in breast
cancer derived cells [5,6]. TXNIP is also regulated by
GC and is one of the genes that predicts apoptotic sen-
sitivity to GC as recently shown in the gene expression
profiling of leukemic cells and primary thymocytes [13].
W es h o wt h a tT X N I P - R O S - T R Xa x i si sf u n c t i o n a li n
response to glucose in 3 out of 4 MM cell lines tested
and TXNIP RNA level is responsive to DEX in the same
3 cell lines. Although the met a b o l i ca x i sr e s p o n d st o
glucose or DEX with a various magnitude, this is
Figure 4 A. Blocking glucose transport blocks the hyperglycemia effect oon thioredoxin-interacting protein (TXNIP) RNA levels.C e l l s
were grown in 5 mM glucose or 20 mM chronically.. For glucose uptake inhibition, phlor (200 μM) was added to 20 mM media and cells
harvested after 24 hours. Fold change is based on comparison to 5 mM glucose. B. Reactive oxygen species (ROS)-levels in response to phlor
pre-treatment. Cells were treated as in A. ROS levels were measured as mean fluorescence of 50,000 cells and compared to 5 mM as baseline.
Figure 5 Hyperglycemia increase the DEX-IC50 in MM cells . Cells were grown in 5 or 20 mM glucose chronically. Dexamethasone, in varying
concentrations, was added for 24 hour after which cells were harvested. IC50 was calculated using Calcusyn software and represented as median
dose response. A. ARH77 response B. MC/CAR response.
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suggest that TRX activity might be directly regulated by
glucose or DEX in these cells that have unchanged
levels of TXNIP RNA, a major endogenous inhibitor of
TRX activity [14]. The direct regulation of TRX activity
by glucose has been described in diabetic rat heart but
never in cancerous cells [15]. Thioredoxin reductase 1, a
major regulator of TRX oxidation, is GC-sensitive as
shown in epithelial cells [16]. Although we have not
investigated the mechanism in MM cells U266B1, we
speculate that the metabolic conditions triggered by an
excess of glucose or directly by DEX activates the TRX
system to scavenger the excess of ROS that would have
otherwise occurred, particularly when TXNIP is downre-
gulated. Obviously, this point needs to be proven in
future studies.
Gatenby and Gilles have recently described the depen-
dence of highly proliferative cancerous cells upon aero-
bic glycolysis [17]. This acquired phenotype highly
depends on persistent glucose metabolism to lactate in
c o n d i t i o n so fh y p o x i a[ 1 7 ] .W eh a v es h o w nt h a tt h e
shift to lactate metabolism in excess of glucose is asso-
ciated with increased levels of TXNIP protein that
increases ROS levels through inhibition of TRX activity
in breast cancer derived cells MDA-MB-231 [5,6]. We
show for the first time that a similar mechanism oper-
ates in some MM cell lines at various degree of effi-
ciency. We also show for the first time that the same
MM cells respond to DEX-mediated TXNIP regulation.
Surprisingly, we also observe a glucose-sensitive
response of MM cells to DEX that makes the cells less
susceptible to the cytotoxic effects of the drug. This
observation was unexpected because we anticipated that
TXNIP regulation would have been enforced by the
combination of glucose and DEX both containing
responsive elements in the regulatory part of TXNIP
gene. In fact, glucose or DEX was individually able to
exert TXNIP regulation at various degrees in responsive
cells. Their effect was though not augmented by the
combined exposure of the cells as expected. One possi-
ble explanation might be that ChoRE and GC-RE are
competing with each other or that the action of DEX
prevails on the glucose by mechanism directly interfer-
ing with ROS production outside the nucleus in those
MM cells, ARH77 and MC/CAR. Obviously, the specu-
lation portends further work in support of the hypoth-
esis. Furthermore, DEX and glucose may exert their
effects outside the nucleus at the level of mitochondria
where ROS are mainly produced. In fact, evidence sug-
gests that TXNIP triggers activation of nuclear tran-
scription regulation by MondoA at the mitochondrial
level, which favors cross talk between mitochondria and
nucleus [18,19]. Emerging pathways of non-genomic GC
signaling involving direct action of GC on the
mitochondria have been recently described in T cells
and neurons [20,21]. Although a recent study has shown
that DEX-induced oxidative stress enhances radio-sensi-
tization of MM cells, this effect was not studied in con-
ditions of hyperglycemia [22].
Conclusions
In conclusion, although our study elucidates never-
described before regulation of glucose and DEX of
important components of ROS regulation through
TXNIP modulation or direct interference with TRX
activity, we are well aware of the limitations of the study
itself. First our study is a very preliminary study that ori-
ginates hypothesis and consider the relevance of the
metabolic conditions of the host (diabetes, hyperglyce-
mia, etc) rather than the relevance of diabetes as a cause
of malignance. Whether this has consequences on the
response to therapy or not needs to be assessed. Second,
our study lacks both the elucidation of the mechanisms
underlying our observation and the validation of the
observation itself in cells directly and freshly isolated
from patients. The easy way to validate the concept will
be to analyze survival and disease free survival/end
points retrospectively in patients with multiple myeloma
treated with DEX in conditions of hyperglycemia versus
normal glycemia. Despite the limitation that EBV-
infected cell lines (ARH-77 and MC/CAR) may pose as
results and the fact that normal control cell counter-
parts are lacking in our study, we still believe that we
represent a grading of response in the four cell lines
tested that reflect the heterogeneity of cells undergone
malignant transformation. For the first time, we show
that glucose modulates the activity of DEX and this
action seems mainly involving pathways regulating ROS
in MM cells. Whether this finding will help in reducing
DEX toxicity or improving its efficacy particularly in
combination with other agents remains unclear. A better
understanding of these pathways may help in improving
the efficacy and reducing the toxicity of DEX, a drug
still highly used in the treatment of MM. Our study also
set the ground to study the relevance of the metabolic
milieu in affecting drug response and toxicity in diabetic
versus non-diabetic patients with MM
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